Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a […]


Ewopharma is pleased to report an important new regulatory milestone for sugemalimab licensed from Chinese partner CStone Pharmaceuticals. In late November 2025, the European Commission (EC) granted approval for a […]
Effective June 1, 2024, Ewopharma AG has the exclusive licence to distribute Translumina’s drug-eluting stents (DES) and Blue Medical’s drug-coated balloon (DCB) technologies in Bulgaria. The agreement includes two key […]

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of AllergyCare AG, a Swiss distribution company of pharmaceutical […]
Ewopharma announces today that it has entered into a strategic commercial collaboration with CStone Pharmaceuticals (“CStone”, HKEX: 2616), an innovationdriven biopharmaceutical company focused on the research and development of anti-cancer […]

Ewopharma AG, a privately held Swiss healthcare group with subsidiaries in Central and Eastern Europe, is pleased to announce its acquisition of Neomed s.r.o., a Czech Distribution company of pharmaceuticals, […]